Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Oliver Sartor MD

Oliver Sartor MD

Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, Minnesota

Dr. Oliver Sartor is a medical oncologist in the Division of Medical Oncology in the Department of Oncology at the Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Genitourinary Cancer Disease Group and the Director of Radiopharmaceutical Clinical Trials for the Mayo Clinic Comprehensive Cancer Center.

Dr. Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval of drugs for advanced prostate cancer (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and, at last count, has given invited lectures in 33 countries. He is the Medical Oncology Chair of the Genitourinary Cancer Committee of NRG, a national cancer research group.

Disclosures

  • Consultant: Advanced Accelerator Applications (AAA); Astellas; AstraZeneca; Bayer; Blue Earth Diagnostics; Bavarian Nordic; Bristol Myers Squibb; Clarity Pharmaceuticals; Clovis; Constellation; Dendreon; EMD Serono; Fusion; Isotopen Technologien Muenchen; Janssen; Merck; Myovant; Myriad; Noria Therapeutics; Novartis; Noxopharm; Progenics; POINT Biopharma; Pfizer; Sanofi; Teneobio; Telix; Theragnostics
  • Research funding: Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Constellation; Endocyte; Invitae; Janssen; Lantheus; Merck; Progenics; Teneobio

Recent Contributions to PracticeUpdate:

  1. Niraparib in Combination With Abiraterone Acetate and Prednisone vs Abiraterone Acetate and Prednisone for Treatment of Metastatic Prostate Cancer
  2. Darolutamide and Survival in Prostate Cancer
  3. Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-Resistant Prostate Cancer
  4. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
  5. Darolutamide in Metastatic and Hormone-Sensitive Prostate Cancer
  6. 2021 Top Story in Advanced Prostate Cancer: The Promise of PSMA PET
  7. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer
  8. Fracture Risk and Radium-223 for Metastatic Prostate Cancer
  9. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing
  10. Germline ATM vs BRCA2 Mutations Affecting Therapy Outcomes in Prostate Cancer

Most Read This Week

Recently Updated